Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cleveland BioLabs, Inc. (OQ:CBLI)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEC Form 4 filings for CBLI*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 20, 2020 21:27 ET
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm – PE, CEIX, CBLI
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Parsley Energy, Inc. (NYSE: PE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Pioneer...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.64
--
--
Price to Sales - TTM
63.04
8.61
5.93
Price to Book - most recent quarter
--
3.79
3.61
Price to Cash Flow per share - TTM
--
17.51
16.78
Price to Free Cash Flow per share - TTM
--
35.87
26.72
See all valuations

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

See business summary

 

Twitter

Search (past week) for $CBLI